



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Document Number 10000007837
 Product Name Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC
 Pure substance/mixture Mixture

DocuSigned by:

 1A130E8E320B4AF...
 2023-03-03

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Laboratory reagent
 Uses advised against No information available

1.3. Details of the supplier of the safety data sheet

Manufacturer

STEMCELL Technologies SARL
 40 Rue des Berges, Miniparc Polytec, Bâtiment Sirocco, 38000 Grenoble, France
 +33 (0) 4 76 04 75 30
 STEMCELL Technologies Germany GmbH
 Stolberger Str. 200, 50933, Köln, Germany
 +33 (0) 4 76 04 75 30
 STEMCELL Technologies UK Ltd.
 Building 7100, Cambridge Research Park, Beach Drive, Waterbeach, Cambridge, UK, CB25 9TL
 +33 (0) 4 76 04 75 30

For further information, please contact

1.4. Emergency telephone number

Emergency Telephone No information available

Emergency Telephone - \$45 - (EC)1272/2008
Europe 112

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Regulation (EC) No 1272/2008

This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP]



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

2.2. Label elements

This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP]

Hazard statements

This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP]

2.3. Other hazards

No information available

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Synonyms

Not applicable

3.2 Mixtures

The product contains no substances which at their given concentration, are considered to be hazardous to health

This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP]

Full text of H- and EUH-phrases: see section 16

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Wash skin with soap and water. In the case of skin irritation or allergic reactions see a physician.
Ingestion	Clean mouth with water and drink afterwards plenty of water.

4.2. Most important symptoms and effects, both acute and delayed

Symptoms No information available.

4.3. Indication of any immediate medical attention and special treatment needed



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Note to physicians

Treat symptomatically.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable Extinguishing Media

No information available.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical

No information available.

5.3. Advice for firefighters

Special protective equipment for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions

Ensure adequate ventilation.

For emergency responders

Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions

See Section 12 for additional Ecological Information.

6.3. Methods and material for containment and cleaning up

Methods for containment

Prevent further leakage or spillage if safe to do so.

Methods for cleaning up

Take up mechanically, placing in appropriate containers for disposal.

Prevention of secondary hazards

Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Ensure adequate ventilation.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store in accordance with information listed on the Product Information Sheet (PIS).

7.3. Specific end use(s)

Identified Uses

Risk Management Methods (RMM) The information required is contained in this Material Safety Data Sheet.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

Derived No Effect Level (DNEL) No information available.

Predicted No Effect Concentration (PNEC) No information available.

8.2. Exposure controls

Personal protective equipment

Eye/face protection No special protective equipment required.



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Skin and body protection	No special protective equipment required.
Respiratory protection	No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.
Environmental exposure controls	No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Liquid
Appearance	Clear
Color	No information available
Odor	No data available.
Odor threshold	No data available

<u>Property</u>	<u>Values</u>	<u>Remarks • Method</u>
pH	No data available	None known
Melting point / freezing point	No data available	None known
Boiling point / boiling range	No data available	None known
Flash point	No data available	None known
Evaporation rate	No data available	None known
Flammability (solid, gas)	No data available	None known
Flammability Limit in Air		None known
Upper flammability limit:	No data available	
Lower flammability limit:	No data available	
Vapor pressure	No data available	None known
Vapor density	No data available	None known
Relative density	No data available	None known
Water solubility	No data available	None known
Solubility(ies)	No data available	None known
Partition coefficient	No data available	None known
Autoignition temperature	No data available	None known
Decomposition temperature	No data available	None known
Kinematic viscosity	No data available	None known
Dynamic viscosity	No data available	None known
Explosive properties	No information available	

Oxidizing properties No information available

9.2. Other information

Softening point No information available



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Molecular weight	No information available
Molecular formula	No information available
VOC Content (%)	No information available
Liquid Density	No information available
Bulk density	No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under recommended transport or storage conditions.

Explosion data

Sensitivity to Mechanical Impact None.

Sensitivity to Static Discharge None.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions None under normal processing.

10.4. Conditions to avoid

Conditions to avoid None known based on information supplied.

10.5. Incompatible materials

Incompatible materials None known based on information supplied.

10.6. Hazardous decomposition products

Hazardous decomposition products None known based on information supplied.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on toxicological effects

Information on likely routes of exposure

Product Information

.



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Inhalation	Specific test data for the substance or mixture is not available.
Eye contact	Specific test data for the substance or mixture is not available.
Skin contact	Specific test data for the substance or mixture is not available.
Ingestion	Specific test data for the substance or mixture is not available.

Symptoms related to the physical, chemical and toxicological characteristics

Symptoms No information available.

Numerical measures of toxicity

Acute toxicity

Unknown acute toxicity 0 % of the mixture consists of ingredient(s) of unknown toxicity.
 0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity.
 100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas).
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor).
 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

Product Information

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation No information available.

Product Information

Serious eye damage/eye irritation No information available.

Product Information

Respiratory or skin sensitization No information available.

Product Information

Germ cell mutagenicity No information available.

Product Information

Carcinogenicity No information available.

Product Information



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Reproductive toxicity No information available.

Product Information

STOT - single exposure No information available.

Product Information

STOT - repeated exposure No information available.

Product Information

Aspiration hazard No information available.

Section 12: ECOLOGICAL INFORMATION

12.1. Toxicity

Ecotoxicity

Unknown aquatic toxicity Contains 0 % of components with unknown hazards to the aquatic environment.

Product Information

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

12.6. Other adverse effects

Other adverse effects No information available.

Section 13: DISPOSAL CONSIDERATIONS



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

13.1. Waste treatment methods

Waste from residues/unused products	Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.
Contaminated packaging	Do not reuse empty containers.

Section 14: TRANSPORT INFORMATION

IMDG

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Marine pollutant	Not applicable
14.6 Special Provisions	None
14.7. Transport in bulk according to Annex II of MARPOL and the IBC Code	No information available

RID

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None

ADR

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None

IATA

14.1 UN Number	Not regulated
14.2 UN proper shipping name	Not regulated
14.3 Transport hazard class(es)	Not regulated
14.4 Packing Group	Not regulated
14.5 Environmental hazard	Not applicable
14.6 Special Provisions	None



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009 Not applicable

International Inventories

TSCA	Complies
DSL/NDSL	Complies
EINECS/ELINCS	Complies
ENCS	Does not comply
IECSC	Complies
KECL	Complies
PICCS	Complies
AICS	Complies

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing and Evaluated Chemical Substances
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available



SAFETY DATA SHEET

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision Date 28-Feb-2023

Revision Number 1.1

100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Legend

SVHC: Substances of Very High Concern for Authorization:

Legend Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

TWA	TWA (time-weighted average)	STEL	STEL (Short Term Exposure Limit)
Ceiling	Maximum limit value	*	Skin designation

Revision Date 28-Feb-2023

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

Certificate Of Completion

Envelope Id: 91DDA77F6F0E4A38A1E9F543871BA1A6

Status: Completed

Subject: Complete with DocuSign: 10000007837-SDS_1_1_EU.pdf

Source Envelope:

Document Pages: 11

Signatures: 1

Certificate Pages: 5

Initials: 0

AutoNav: Enabled

Envelopeld Stamping: Enabled

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Envelope Originator:

Cory Thomson

1618 Station Street

Suite 500

Vancouver, BC V6A 1B6

cory.thomson@stemcell.com

IP Address: 207.216.179.12

Record Tracking

Status: Original

2023-03-03 | 06:14

Holder: Cory Thomson

cory.thomson@stemcell.com

Location: DocuSign

Signer Events


Ruth Gill

ruth.gill@stemcell.com

Program Lead, Official Documentation

Security Level: Email, Account Authentication
(None)**Signature**

DocuSigned by:



1A130E8E320B4AF...

Signature Adoption: Pre-selected Style

Using IP Address: 50.68.4.162

Timestamp

Sent: 2023-03-03 | 06:15

Viewed: 2023-03-03 | 08:07

Signed: 2023-03-03 | 08:07

Electronic Record and Signature Disclosure:

Accepted: 2021-03-09 | 09:57

ID: 31751331-06db-4fcc-aecd-87e677f32d84

In Person Signer Events**Signature****Timestamp****Editor Delivery Events****Status****Timestamp****Agent Delivery Events****Status****Timestamp****Intermediary Delivery Events****Status****Timestamp****Certified Delivery Events****Status****Timestamp****Carbon Copy Events****Status****Timestamp**

Sharon McAuliffe

sharon.mcauliffe@stemcell.com

Security Level: Email, Account Authentication
(None)**COPIED**

Sent: 2023-03-03 | 08:07

Electronic Record and Signature Disclosure:

Accepted: 2023-02-06 | 09:51

ID: d3613b64-739c-4528-9db6-5aac2c0b1cba

Paula Liao

paula.liao@stemcell.com

Security Level: Email, Account Authentication
(None)**COPIED**

Sent: 2023-03-03 | 08:07

Viewed: 2023-03-03 | 12:25

Electronic Record and Signature Disclosure:

Not Offered via DocuSign

QAS Document Control

qasdocumentcontrol@stemcell.com

Security Level: Email, Account Authentication
(None)**COPIED**

Sent: 2023-03-03 | 08:07

Viewed: 2023-03-03 | 12:55

Carbon Copy Events	Status	Timestamp
--------------------	--------	-----------

Electronic Record and Signature Disclosure:
Accepted: 2022-05-17 | 11:26
ID: 2ee418fd-3f48-4d7e-bf1e-7156f1149617

Witness Events	Signature	Timestamp
----------------	-----------	-----------

Notary Events	Signature	Timestamp
---------------	-----------	-----------

Envelope Summary Events	Status	Timestamps
-------------------------	--------	------------

Envelope Sent	Hashed/Encrypted	2023-03-03 06:15
Certified Delivered	Security Checked	2023-03-03 08:07
Signing Complete	Security Checked	2023-03-03 08:07
Completed	Security Checked	2023-03-03 08:07

Payment Events	Status	Timestamps
----------------	--------	------------

Electronic Record and Signature Disclosure
--

CONSUMER DISCLOSURE

From time to time, Stemcell Technologies Inc (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after signing session and, if you elect to create a DocuSign signer account, you may access them for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Stemcell Technologies Inc:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: adam.leggett@stemcell.com

To advise Stemcell Technologies Inc of your new e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at adam.leggett@stemcell.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in the DocuSign system.

To request paper copies from Stemcell Technologies Inc

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to adam.leggett@stemcell.com and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Stemcell Technologies Inc

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to adam.leggett@stemcell.com and in the body of such request you must state your e-mail, full name, US Postal Address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

Operating Systems:	Windows® 2000, Windows® XP, Windows Vista®; Mac OS® X
Browsers:	Final release versions of Internet Explorer® 6.0 or above (Windows only); Mozilla Firefox 2.0 or above (Windows and Mac); Safari™ 3.0 or above (Mac only)
PDF Reader:	Acrobat® or similar software may be required to view and print PDF files
Screen Resolution:	800 x 600 minimum

Enabled Security Settings:	Allow per session cookies
----------------------------	---------------------------

** These minimum requirements are subject to change. If these requirements change, you will be asked to re-accept the disclosure. Pre-release (e.g. beta) versions of operating systems and browsers are not supported.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify Stemcell Technologies Inc as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by Stemcell Technologies Inc during the course of my relationship with you.